Your browser doesn't support javascript.
mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021.
Nunes, Baltazar; Rodrigues, Ana Paula; Kislaya, Irina; Cruz, Camila; Peralta-Santos, André; Lima, João; Pinto Leite, Pedro; Sequeira, Duarte; Matias Dias, Carlos; Machado, Ausenda.
  • Nunes B; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Rodrigues AP; Centro de Investigação em Saúde Pública, Escola Nacional de Saúde Pública, Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Kislaya I; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Cruz C; Departamento de Epidemiologia, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Peralta-Santos A; Centro de Investigação em Saúde Pública, Escola Nacional de Saúde Pública, Universidade NOVA de Lisboa, Lisbon, Portugal.
  • Lima J; Direção do Centro Nacional de TeleSaúde, Serviços Partilhados do Ministério da Saúde, Lisbon, Portugal.
  • Pinto Leite P; Direção de Serviços de Informação e Análise, Direção-Geral da Saúde, Lisbon, Portugal.
  • Sequeira D; Direção do Centro Nacional de TeleSaúde, Serviços Partilhados do Ministério da Saúde, Lisbon, Portugal.
  • Matias Dias C; Direção de Serviços de Informação e Análise, Direção-Geral da Saúde, Lisbon, Portugal.
  • Machado A; Direção do Centro Nacional de TeleSaúde, Serviços Partilhados do Ministério da Saúde, Lisbon, Portugal.
Euro Surveill ; 26(38)2021 09.
Article in English | MEDLINE | ID: covidwho-1496926
ABSTRACT
Through deterministic data linkage of health registries, mRNA vaccine effectiveness (VE) against COVID-19-related hospitalisations and deaths was measured in 1,880,351 older adults. VE against hospitalisations was 94% (95% confidence interval (CI) 88-97) and 82% (95% CI 72-89) for those 65-79 and ≥ 80 years old, with no evidence of waning 98 days after dose two. VE against mortality was 96% (95% CI 92-98) and 81% (95% CI 74-87) in these two age groups.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.38.2100833

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Aged / Humans Country/Region as subject: Europa Language: English Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: 1560-7917.ES.2021.26.38.2100833